David G Oscier
Overview
Explore the profile of David G Oscier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirandari A, Parker H, Ashton-Key M, Stevens B, Walewska R, Stamatopoulos K, et al.
Explor Target Antitumor Ther
. 2024 Sep;
5(4):877-901.
PMID: 39280243
Splenic marginal zone lymphoma (SMZL) is a rare, predominantly indolent B-cell lymphoma constituting fewer than 2% of lymphoid neoplasms. However, around 30% of patients have a shorter survival despite currently...
2.
Carr L, Norris K, Parker H, Nilsson-Takeuchi A, Bryant D, Amarasinghe H, et al.
Br J Haematol
. 2024 Sep;
205(5):2072-2076.
PMID: 39253978
No abstract available.
3.
Blakemore S, Clifford R, Parker H, Antoniou P, Stec-Dziedzic E, Larrayoz M, et al.
Leukemia
. 2020 Feb;
34(7):1760-1774.
PMID: 32015491
Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy remains a central treatment modality, with chemotherapy trials representing an invaluable resource to explore disease-related/genetic features contributing to long-term outcomes....
4.
Wojdacz T, Amarasinghe H, Kadalayil L, Beattie A, Forster J, Blakemore S, et al.
Blood Adv
. 2019 Aug;
3(16):2474-2481.
PMID: 31434681
Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes (IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to chemoimmunotherapy (CIT). DNA methylation profiling can subdivide early-stage patients into...
5.
6.
Parker H, McIver-Brown N, Davis Z, Parry M, Rose-Zerilli M, Xochelli A, et al.
Blood Adv
. 2018 May;
2(10):1116-1119.
PMID: 29773550
No abstract available.
7.
Robles E, Mena-Varas M, Barrio L, Merino-Cortes S, Balogh P, Du M, et al.
Nat Commun
. 2016 Jun;
7:11889.
PMID: 27297662
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not...
8.
Winkelmann N, Rose-Zerilli M, Forster J, Parry M, Parker A, Gardiner A, et al.
Haematologica
. 2015 Feb;
100(6):e237-9.
PMID: 25710457
No abstract available.
9.
Hillmen P, Gribben J, Follows G, Milligan D, Sayala H, Moreton P, et al.
J Clin Oncol
. 2014 Mar;
32(12):1236-41.
PMID: 24638012
Purpose: Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For this population, chlorambucil monotherapy is an appropriate therapeutic...
10.
Rose-Zerilli M, Forster J, Parker H, Parker A, Rodriguez A, Chaplin T, et al.
Haematologica
. 2014 Mar;
99(4):736-42.
PMID: 24584352
ATM mutation and BIRC3 deletion and/or mutation have independently been shown to have prognostic significance in chronic lymphocytic leukemia. However, the relative clinical importance of these abnormalities in patients with...